The Q1 2023 quarterly report can be accessed using the link below
Dedicated to the treatment of metabolic, fibrotic and inflammatory diseases using our drug discovery platform and data-driven approach
About us
Liminal BioSciences is a development-stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for metabolic, fibrotic and inflammatory diseases using our drug discovery platform and data-driven approach.
Product pipeline
Our expertise in small molecules has enabled a strong pipeline with potential first/best-in-class drug candidates.